Year: 2025

Global Water Resources Reports Second Quarter 2025 Results

Written by Customer Service on August 13, 2025. Posted in Earnings Releases And Operating Results.

PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) — Global Water Resources, Inc. (NASDAQ: GWRS), a pure-play water resource management company, reported results for the second quarter ended June 30, 2025. All comparisons are to the same year-ago period unless otherwise noted. The company will hold a conference call at 1:00 p.m. Eastern time tomorrow to discuss the results (see dial-in information below). Q2 2025 Financial HighlightsTotal revenue increased 5.4% to $14.2 million, primarily due to organic connection growth, increased consumption and higher rates. Net income decreased to $1.6 million or $0.06 per share from $1.7 million or $0.07 per share. One of the primary drivers of this decline is due to the company’s capital improvement plan, which has resulted in a related increase in depreciation expense. Adjusted EBITDA, a non-GAAP...

Astrotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference in September 2025

Written by Customer Service on August 13, 2025. Posted in Public Companies.

AUSTIN, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) — Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) today announced that Thomas B. Pickens III, Chairman and Chief Executive Officer, and Jennifer Cañas, Chief Financial Officer, will host investor meetings on Tuesday, September 9, 2025 as part of the H.C. Wainwright 27th Annual Global Investment Conference in New York City taking place at the Lotte New York Palace Hotel. Investors can register and request meetings with management via their HC Wainwright representative or Astrotech Investor Relations at mkreps@darrowir.com. About Astrotech Corporation Astrotech Corporation is a mass spectrometry company that creates, operates, and scales innovative businesses through its wholly owned subsidiaries. Each subsidiary leverages Astrotech’s core technology to serve specialized...

Brookfield Corporation Announces Pricing of $650 Million Notes Due 2036

Written by Customer Service on August 13, 2025. Posted in Public Companies.

BROOKFIELD, NEWS, Aug. 13, 2025 (GLOBE NEWSWIRE) — Brookfield Corporation (“Brookfield”) (NYSE: BN, TSX: BN) today announced the pricing of a public offering of $650 million principal amount of senior notes due 2036 (the “notes”), which will bear interest at a rate of 5.330% per annum. The offering is expected to close on August 20, 2025, subject to the satisfaction of customary closing conditions. The notes will be issued by Brookfield Finance Inc., an indirect wholly-owned subsidiary of Brookfield, and will be fully and unconditionally guaranteed by Brookfield. It is expected that the net proceeds from the sale of the notes will be used for general corporate purposes. The notes are being offered under Brookfield and the issuer’s existing base shelf prospectus filed in the United States and Canada and pursuant to an effective...

Gulf Resources, Inc. Announces Second Quarter 2025 Unaudited Financial Results

Written by Customer Service on August 13, 2025. Posted in Earnings Releases And Operating Results.

SHOUGUANG, China, Aug. 13, 2025 (GLOBE NEWSWIRE) — Gulf Resources, Inc. (Nasdaq: GURE) (“Gulf Resources,” “we,” or the “Company”), a leading manufacturer of bromine, crude salt and specialty chemical products in China today announced its unaudited financial results for the three months ended June 30, 2025. The company reported:Net Revenue increased by 250% to $8,343,785 from $2,383,169 in the previous year. Gross profits increased to $986,655 from a loss of $2,728,889. The loss from operations was $750,686 compared to a loss of $5,146,997. The net loss was $773,777 versus a net loss of $33,097,918 in the previous period. The Loss per share was $0.06 versus a loss of $3.09 in the previous period. Negative cash flow for the 6 months of 2025 was sharply reduced from $61,856,355 to $2,339,081.On a segment basis BromineBromine...

Planet 13 Announces Q2 2025 Financial Results

Written by Customer Service on August 13, 2025. Posted in Earnings Releases And Operating Results.

Q2 2025 Revenue of $26.9 millionQ2 2025 Net loss of $13.3 millionQ2 2025 Adjusted EBITDA loss of $2.4 millionAll figures are reported in United States dollars ($) unless otherwise indicated LAS VEGAS, Aug. 13, 2025 (GLOBE NEWSWIRE) — Planet 13 Holdings Inc. (CSE: PLTH) (OTCQX: PLNH) (“Planet 13” or the “Company”), a leading vertically-integrated multi-state cannabis company, today announced its financial results for the three-month period ended June 30, 2025. Planet 13’s financial statements are prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). “Q2 played out in a tough operating environment. Against that backdrop, we remained sharply focused on what we can control, driving efficiencies and cutting costs. At the same time, we took bold steps to maximize our scale advantage in Nevada, moving...

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Written by Customer Service on August 13, 2025. Posted in Earnings Releases And Operating Results.

First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical hold, triggering a $10M milestone payment from GSK. An additional $20M milestone will be triggered upon the six month anniversary of the new patient dosing; as previously disclosed GSK disputes these milestone payments. SCYNEXIS vigorously disagrees with GSK’s position and is working towards resolving this disagreement;SCYNEXIS is actively working with GSK to transfer the BREXAFEMME New Drug Application (NDA) to GSK by the end of this year, ahead of anticipated GSK Regulatory interactions in 2026 to discuss the relaunch of the product.The Company anticipates reporting Phase 1 Single Ascending Dose/Multiple Ascending Dose (SAD/MAD) data for SCY-247 (oral) in Q3 2025Regarding the November 2023 securities class action, that was filed by Brian...

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

Written by Customer Service on August 13, 2025. Posted in Earnings Releases And Operating Results.

– Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful vision restoration with OPGx-LCA5 – – FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation for OPGx-LCA5 – – Positive topline results reported from VEGA-3 and LYNX-2 Phase 3 trials with Phentolamine Ophthalmic Solution 0.75% – – OPGx-BEST1 on track to enter Phase 1/2 trial in H2 2025 for the treatment of bestrophin-1 related inherited retinal disease – – Non-dilutive funding from patient advocacy groups secured to advance multiple early-stage gene therapy programs – RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical...

Aptose Reports Second Quarter 2025 Results

Written by Customer Service on August 13, 2025. Posted in Earnings Releases And Operating Results.

Tuspetinib Continues to Demonstrate Excellent Safety and Complete Responses in the TUSCANY Clinical Trial of Tuspetinib in AML Triple Drug Frontline Therapy at 120 mg DoseCohort Safety Review Committee (CSRC) Recommends Tuspetinib Dose Escalation to 160 mg DoseHanmi Continues to Support Development of TuspetinibSAN DIEGO and TORONTO, Aug. 13, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced financial results for the second quarter ended June 30, 2025, and provided a corporate update. “During the second quarter, the TUSCANY triplet trial continued to progress well. Our investigators...

Birchcliff Energy Ltd. Announces Q2 2025 Results, Strong New Well Performance and Declares Q3 2025 Dividend

Written by Customer Service on August 13, 2025. Posted in Dividend Reports And Estimates.

CALGARY, Alberta, Aug. 13, 2025 (GLOBE NEWSWIRE) — Birchcliff Energy Ltd. (“Birchcliff” or the “Corporation”) (TSX: BIR) is pleased to announce its Q2 2025 financial and operational results and provide an operational update with respect to its 2025 capital program. Chris Carlsen, Birchcliff’s President and Chief Executive Officer, commented: “Our strong operational and financial performance continued during the second quarter of 2025. We maintained our focus on operational excellence and efficient execution and benefitted from the performance of the initial wells of our 2025 capital program, achieving second quarter average production of 79,480 boe/d. The 12 wells brought on production in Q2 2025 targeted high-value condensate-rich natural gas, yielding attractive netbacks. Adjusted funds flow(1) for Q2 2025 was $94.5 million and...

Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results

Written by Customer Service on August 13, 2025. Posted in Earnings Releases And Operating Results.

Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clinical study of NPM-115 New $10M equity financing to enable accelerated development of NPM-139 while securing financial position into the second half of 2026 Vivani to spin off Cortigent, Inc., a division of the Company that develops brain implant devices to help patients recover critical body functions, as an independent publicly traded company ALAMEDA, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) — Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, ultra long-acting drug implants, today reported financial results for the second quarter ended June 30, 2025, and provided a...

Year: 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals